Insmed (INSM) Earnings Date & Reports

Insmed posted total net product revenues of $306.0 million for the first quarter ended March 31, 2026, surpassing analyst consensus of approximately $301.5 million and soaring 230% from $92.8 million in Q1 2025. BRINSUPRI drove the growth with $207.9 million ($207.2 million U.S., $0.7 million international), up 44% sequentially from Q4 2025's $144 million base following its August 2025 launch. ARIKAYCE contributed $98.1 million (U.S. $62.9 million, down 2% YoY; international $35.2 million, up 23% YoY), in line with prior quarterly guidance of low- to mid-$20 million range.

The GAAP net loss improved to $163.6 million, or $0.76 per diluted share, from $256.6 million or $1.42 per share a year ago, exceeding expectations of -$0.96 to -$0.98 (20-22% beat). This reflects operating leverage despite R&D and SG&A (selling, general, and administrative) expenses rising on commercialization and pipeline investments. Insmed reiterated full-year 2026 guidance: BRINSUPRI at least $1 billion, ARIKAYCE $450 million to $470 million. Cash and equivalents plus marketable securities stood at ~$1.2 billion as of March 31.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Despite the earnings beat, Insmed shares plunged over 23% on May 7, closing around $105, with pre-market drops exceeding 14% and intraday lows near $104. Investors sold off amid disappointment over unrevised guidance despite BRINSUPRI's strong start, rising operating expenses (R&D up to $209.5 million, SG&A to $247.3 million), and recent CEO share sales under a 10b5-1 plan. Sentiment reflects concerns on profitability timeline, even as pipeline wins like ARIKAYCE's Phase 3b ENCORE success buoyed some views.

Forward Outlook and Key Factors to Monitor

Insmed's reiterated 2026 revenue guidance underscores confidence in BRINSUPRI's U.S. trajectory and international expansion, including UK approval and pending Japan decision. ARIKAYCE's ENCORE study success supports supplemental New Drug Application (sNDA) to FDA in H2 2026 for broader MAC (Mycobacterium avium complex) lung disease label, potentially doubling the market, with PMDA (Pharmaceuticals and Medical Devices Agency) review in Japan.

Pipeline catalysts include Phase 3 PALM-PAH initiation for TPIP in pulmonary arterial hypertension (PAH), ongoing PALM-ILD for pulmonary hypertension in interstitial lung disease (PH-ILD), and open-label extension data from Phase 2b in Q3 2026. Investors should track TPIP Phase 3 starts in progressive pulmonary fibrosis (PPF) by year-end and idiopathic pulmonary fibrosis (IPF) in H1 2027, plus early-stage programs like INS1148 and INS1033 (IND H2 2026).

Balance sheet strength (~$1.2 billion cash) funds operations toward 2027 cash-flow positivity goal, but monitor expense trends, gross margins, and payer dynamics for BRINSUPRI. Upcoming ATS 2026 presentations (May 15-20) and Q2 earnings will provide uptake updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations